Jacqueline Claudia Barrientos, MD

Assistant Professor, Division of Hematology and Medical Oncology,
Department of Medicine, Hofstra Northwell School of Medicine

Phone: (516) 470-4050
Email: jbarrientos@northwell.edu

About the Investigator

Dr. Barrientos is a principal investigator of numerous clinical research studies from early stage development to registration trials investigating new CLL therapies at the Northwell Health Cancer Institute’s CLL Research and Treatment Program on Long Island. She was involved in the pivotal trials that led to the approval of novel therapeutic agents that target dysregulated pathways in leukemia and lymphoma. She has extensive experience with the novel BTK inhibitors ibrutinib and acalabrutinib, with the PI3Kd inhibitor idelalisib, and the BCL2 inhibitor venetoclax.

Research Focus

Dr. Barrientos works in close collaboration with her mentors, Dr. Kanti R. Rai and Dr. Nicholas Chiorazzi of the Feinstein Institute for Medical Research. My research focus is on chronic lymphocytic leukemia and lymphoma. She has extensive experience with the new promising agents targeting the B-cell receptor signaling pathway in B-cell malignancies, serving as principal investigator on several phase I-III clinical trials. She actively participates in multi-institutional clinical trials with the Chronic Lymphocytic Leukemia Research Consortium (CRC) and the Alliance for Clinical Trials in Oncology.

Lab Members
Education

Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY
Degree: Clinical Fellow
2009
Field of Study: Hematology and Medical Oncology

Clinical and Translational Science Center at the Weill Medical College of Cornell University
Degree: Clinical Investigation
2008

Yale School of Medicine, Yale New Haven Hospital, New Haven, CT
Degree: Internship and Residency
2005
Field of Study: Internal Medicine

Mayagüez Medical Center, Ponce School of Medicine, Puerto Rico
Degree: Transitional
2002

Ponce School of Medicine, Puerto Rico
Degree: MD
2001

University of Puerto Rico at Mayagüez, Puerto Rico
Degree: BS
1996
Field of Study: Biology

Honors and Awards

2015 ASH-AMFDP Career Development Award (Robert Wood Johnson Foundation)
2014 The Spielman Award for Excellence in Research Dept of Medicine, Hofstra North Shore-LIJ School of Med
2014 Cancer and Leukemia Group B (CALGB) Leukemia Committee Cadre Member
2013 Invited Speaker 1st Ibero-American Meeting on CLL (Uruguay)
2013 Invited Speaker Highlights of ASH Latin America
2012 Invited Speaker 2012 ASH® State-of-the-Art Symposium
2008 ASCO Fellows Travel Grant. Sanofi-Aventis
2006 Andlinger Exchange Fellowship. Austrian-American Foundation (Austria)
2006 UVA SMDEP Summer 2006 Special Lecture Series Invited Speaker
2005 Ralph I. Horwitz Research in Residency Award. Yale School of Medicine
2004 Yale/Johnson & Johnson Physician Scholars in International Health (Nepal)
2000 Howard Hughes Medical Institute (Continued Fellowship for Medical Studies)
1999 HHMI-NIH Research Scholars Program
1999–2000 Vice-President Alpha Omega Alpha PR Beta Chapter
1999 Alpha Omega Alpha Medical Honor Society (early induction)
1997 Ponce School of Medicine Summer Research Fellowship
1996 Andrew W. Mellon Fellowship. Summer Research Internship. University of Virginia
1995 Medical Academic Advancement Program (MAAP-I). University of Virginia
1994–1995 President Beta Beta Beta National Biological Honorary Society Zeta Alpha Chapter
1994 Beta Beta Beta National Biological Honorary Society PR Zeta Alpha Chapter

Publications
  1. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. “Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.” The New England journal of medicine. 2013; 369(6):507-16. NIHMSID: NIHMS558061 PubMed [journal] PMID: 23782157, PMCID: PMC4513941
  2. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM. “Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.” The New England journal of medicine. 2014; 370(11):997-1007. NIHMSID: NIHMS609491 PubMed [journal] PMID: 24450857, PMCID: PMC4161365
  3. Rai KR, Barrientos JC. “Movement toward optimization of CLL therapy.” The New England journal of medicine. 2014; 370(12):1160-2. PubMed [journal] PMID: 24645950
  4. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. “Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib.” The New England journal of medicine. 2014; 370(24):2286-94. NIHMSID: NIHMS610518 PubMed [journal] PMID: 24869598, PMCID: PMC4144824
  5. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P. “Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.” The New England journal of medicine. 2014; 371(3):213-23. NIHMSID: NIHMS609690 PubMed [journal] PMID: 24881631, PMCID: PMC4134521
  6. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. “Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.” Nature medicine. 2015; 21(8):922-6. PubMed [journal] PMID: 26193343
  7. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ. “Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.” The New England journal of medicine. 2015; 373(25):2425-37. NIHMSID: NIHMS748304 PubMed [journal] PMID: 26639149, PMCID: PMC4722809
  8. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. “Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.” The New England journal of medicine. 2016; 374(4):323-32. NIHMSID: NIHMS744440 PubMed [journal] PMID: 26641137, PMCID: PMC4862586

View more at PubMed